ReviewBritish journal of pharmacology2012
The dynamic nature of type 1 cannabinoid receptor (CB(1) ) gene transcription.
Review in British journal of pharmacology, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 35 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
35 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Association of CNR1 gene and cannabinoid 1 receptor protein in the human brain.Journal of neuroscience research · 2023Pooled it
- Cannabinoid Receptors: An Update on Cell Signaling, Pathophysiological Roles and Therapeutic Opportunities in Neurological, Cardiovascular, and Inflammatory Diseases.International journal of molecular sciences · 2020Pooled it
- Motion and form perception in healthy individuals with adolescent cannabis use.Frontiers in psychiatry · 2026Article
- Review
- The endocannabinoid system in bovine tissues: characterization of transcript abundance in the growing Holstein steer.BMC veterinary research · 2024Article
- Regulation of Cannabinoid and Opioid Receptor Levels by Endogenous and Pharmacological Chaperones.The Journal of pharmacology and experimental therapeutics · 2024Article
- Correlations of theInternational journal of molecular sciences · 2024Article
- Effects of acute ΔBrain research · 2024Article
- Exploring the therapeutic potential of natural compounds modulating the endocannabinoid system in various diseases and disorders: review.Pharmacological reports : PR · 2023Review
- Cannabinoid Receptor mRNA Expression in Central and Peripheral Tissues in a Rodent Model of Peritonitis.Cannabis and cannabinoid research · 2023Article
- Frequent Low-Dose ΔBiological psychiatry · 2022Article
- Article
- Molecular Insights into Epigenetics and Cannabinoid Receptors.Biomolecules · 2022Review
- Article
- The cannabinoid receptors system in horses: Tissue distribution and cellular identification in skin.Journal of veterinary internal medicine · 2022Article
- Inflammation and Nitro-oxidative Stress as Drivers of Endocannabinoid System Aberrations in Mood Disorders and Schizophrenia.Molecular neurobiology · 2022Review
- Molecular Alterations of the Endocannabinoid System in Psychiatric Disorders.International journal of molecular sciences · 2022Review
- Article
- Cannabis-Induced Malignant Catatonia: A Medical Emergency and Review of Prior Case Series.Cureus · 2021Article
- A novel bioassay for quantification of surface Cannabinoid receptor 1 expression.Scientific reports · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
unlabelledThe type 1 cannabinoid receptor (CB(1) ) is an integral component of the endocannabinoid system that modulates several functions in the CNS and periphery. The majority of our knowledge of the endocannabinoid system involves ligand-receptor binding, mechanisms of signal transduction, and protein-protein interactions. In contrast, comparatively little is known about regulation of CB(1) gene expression. The levels and anatomical distribution of CB(1) mRNA and protein are developmental stage-specific and are dysregulated in several pathological conditions. Moreover, exposure to a variety of drugs, including cannabinoids themselves, alters CB(1) gene expression and mRNA levels. As such, alterations in CB(1) gene expression are likely to affect the optimal response to cannabinoid-based therapies, which are being developed to treat a growing number of conditions. Here, we will examine the regulation of CB(1) mRNA levels and the therapeutic potential inherent in manipulating expression of this gene. LINKED ARTICLES: This article is part of a themed section on Cannabinoids. To view the other articles in this section visit http://dx.doi.org/10.1111/bph.2012.167.issue-8.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.